Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 13/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | PLAU | P00749 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6621517 | 0.83 | ALDH1A1 (0.58) | ALDH1A1NPSR1LMNAPOLBGAA | |
| SCHEMBL2332913 | 0.79 | ADRB2 (0.65) | ALDH1A1ALOX15ADRB2POLBGAA | |
| SCHEMBL26539706 | 0.76 | CYP1A2 (0.47) | ALDH1A1NPSR1ALOX15ADRB2LMNA | |
| SCHEMBL2889813 | 0.74 | ALDH1A1 (0.62) | ALDH1A1NPSR1LMNAPOLBMAPT | |
| SCHEMBL3709323 | 0.73 | ALDH1A1 (0.68) | ALDH1A1NPSR1LMNAPOLBMAPT | |
| SCHEMBL11482764 | 0.73 | KMT2A (0.53) | ALDH1A1NPSR1ALOX15ADRB2LMNA | |
| SCHEMBL7673729 | 0.73 | ALDH1A1 (0.56) | ALDH1A1ALOX15ADRB2LMNAGAA | |
| SCHEMBL2884281 | 0.72 | ALDH1A1 (0.59) | ALDH1A1NPSR1LMNAPOLBGAA | |
| SCHEMBL26983369 | 0.72 | RXFP1 (0.53) | ALDH1A1NPSR1LMNAMAPTL3MBTL1 | |
| SCHEMBL6501728 | 0.72 | KMT2A (0.59) | ALDH1A1ALOX15ADRB2LMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050245503-A1 | Therapeutic heterocycles | ASTRAZENECA AB (SE) | 2005-11-03 | — | — | US | disclosed |
| EP-1458684-A2 | THERAPEUTIC HETEROCYCLES | AstraZeneca AB (SE) | 2004-09-22 | — | — | EP | disclosed |
| WO-2003051276-A2 | THERAPEUTIC HETEROCYCLES | ASTRAZENECA AB (SE) | 2003-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245503-A1 | Therapeutic heterocycles | OPRK1, RECQL, OPRM1 | ALDH1A1 2117/4885NPSR1 80/4885ALOX15 2738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.